346sek
4,2 %
Date:2024-11-25Time:16:41:45Latest report:Q4-2024List:First NorthTicker:NEWBRY
Market Cap:84 msekEnterprise Value:69 msekNet Sales:36,8 msekEarnings:-15,4 msekEmployees:0ISIN:SE0015244884

Ratios

10-year key figure history for Newbury Pharmaceuticals turnover, profit, dividend, equity, PE and PB.

Pre
Pre

Stockprice

Price movement for Newbury Pharmaceuticals with index and moving average MA50 and MA200.

Stockprice:3,46
MA50:3,71
MA200:3,56
Price/MA200:-2,1 %
RSI (14):43,5
Price/MA50:-6,1 %

Description

Newbury Pharmaceuticals is building a pipeline of proprietary and licensed products with focus on specialty and branded products in the Nordics. Newbury aims to make a difference by offering treatment solutions within areas like oncology, rare diseases and neurology. The portfolio is built by leveraging experience and extensive international network. Newbury offers strategic partnerships of innovation for the benefit of the Nordic healthcare market.

Pharmaceuticals